July 2010 Br J Cardiol 2010;17:163-5
BJ Cardio Staff
According to Pfizer, an interim analysis of the trial showed that patients treated with eplerenone in addition to current standard of care experienced a significant reduction in risk of cardiovascular death or heart failure hospitalisation compared with those in the placebo arm of the trial. The company says it is now working to ensure that all patients are informed of this decision, and an amendment to the protocol will be requested to allow all consenting patients to start treatment with eplerenone in an open-label extension of the study, after completing a close-out visit ending the double-blind, placebo-controlled phase. Eplerenone is
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits